193 related articles for article (PubMed ID: 31396797)
1.
Annovazzi A; Anelli V; Zoccali C; Rumi N; Persichetti A; Novello M; Sciuto R; Bertoni F; Ferraresi V; Biagini R
Ann Nucl Med; 2019 Nov; 33(11):813-821. PubMed ID: 31396797
[TBL] [Abstract][Full Text] [Related]
2. The utility of
Zhang Q; Xi Y; Li D; Yuan Z; Dong J
J Orthop Surg Res; 2020 Jun; 15(1):229. PubMed ID: 32571371
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. F-18 FDG PET differentiation of benign from malignant chondroid neoplasms: a systematic review of the literature.
Subhawong TK; Winn A; Shemesh SS; Pretell-Mazzini J
Skeletal Radiol; 2017 Sep; 46(9):1233-1239. PubMed ID: 28608242
[TBL] [Abstract][Full Text] [Related]
5. 18F-FDG PET/CT in Diagnostic and Prognostic Evaluation of Patients With Suspected Recurrence of Chondrosarcoma.
Vadi SK; Mittal BR; Gorla AKR; Sood A; Basher RK; Sood A; Kakkar N; Sen RK
Clin Nucl Med; 2018 Feb; 43(2):87-93. PubMed ID: 29261626
[TBL] [Abstract][Full Text] [Related]
6. Can 18F-FDG PET/CT alone or combined with radiology be used to reliably grade cartilage bone neoplasms for surgical decision making?
Gundavda MK; Agarwal MG; Singh N; Gupta R; Reddy R; Bary A
Nucl Med Commun; 2022 Feb; 43(2):220-231. PubMed ID: 34678831
[TBL] [Abstract][Full Text] [Related]
7. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
[TBL] [Abstract][Full Text] [Related]
8. Can 18F-FDG PET/CT diagnose malignant change in benign chondroid tumors?
Purandare NC; Puranik A; Shah S; Agrawal A; Puri A; Gulia A; Nayak P; Rekhi B; Rangarajan V
Nucl Med Commun; 2019 Jun; 40(6):645-651. PubMed ID: 30921251
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
[TBL] [Abstract][Full Text] [Related]
10. Dual-time point 18FDG-PET/CT imaging may be useful in assessing local recurrent disease in high grade bone and soft tissue sarcoma.
Dancheva Z; Bochev P; Chaushev B; Yordanova T; Klisarova A
Nucl Med Rev Cent East Eur; 2016; 19(1):22-7. PubMed ID: 26841376
[TBL] [Abstract][Full Text] [Related]
11. The role of 18F-FDG PET/CT in staging and restaging primary bone lymphoma.
Liu Y
Nucl Med Commun; 2017 Apr; 38(4):319-324. PubMed ID: 28225435
[TBL] [Abstract][Full Text] [Related]
12. Is Needle Biopsy Clinically Useful in Preoperative Grading of Central Chondrosarcoma of the Pelvis and Long Bones?
Roitman PD; Farfalli GL; Ayerza MA; Múscolo DL; Milano FE; Aponte-Tinao LA
Clin Orthop Relat Res; 2017 Mar; 475(3):808-814. PubMed ID: 26883651
[TBL] [Abstract][Full Text] [Related]
13. ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas.
Li DL; Xu YK; Wang QS; Wu HB; Li HS
Chin Med J (Engl); 2012 Jan; 125(1):91-6. PubMed ID: 22340472
[TBL] [Abstract][Full Text] [Related]
14. Dual-time point
Parghane RV; Basu S
Semin Nucl Med; 2017 Jul; 47(4):373-391. PubMed ID: 28583277
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of 2-[(18)F] fluoro-2-deoxy-D-glucose positron emission tomography in predicting World Health Organization grade in pancreatic neuroendocrine tumors.
Tomimaru Y; Eguchi H; Tatsumi M; Kim T; Hama N; Wada H; Kawamoto K; Kobayashi S; Morii E; Mori M; Doki Y; Nagano H
Surgery; 2015 Feb; 157(2):269-76. PubMed ID: 25311263
[TBL] [Abstract][Full Text] [Related]
16. Differentiation and diagnosis of benign and malignant testicular lesions using 18F-FDG PET/CT.
Shao D; Gao Q; Tian XW; Wang SY; Liang CH; Wang SX
Eur J Radiol; 2017 Aug; 93():114-120. PubMed ID: 28668404
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of soft-tissue lesions with (18)F-FDG PET/CT: initial results of a prospective trial.
Leal AL; Etchebehere M; Santos AO; Kalaf G; Pacheco EB; Amstalden EM; Etchebehere EC
Nucl Med Commun; 2014 Mar; 35(3):252-9. PubMed ID: 24300379
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value and limitations of fluorine-18 fluorodeoxyglucose positron emission tomography for cartilaginous tumors of bone.
Lee FY; Yu J; Chang SS; Fawwaz R; Parisien MV
J Bone Joint Surg Am; 2004 Dec; 86(12):2677-85. PubMed ID: 15590853
[TBL] [Abstract][Full Text] [Related]
19. Role of Combined 68Ga-DOTATOC and 18F-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors: Implications for Managing Surgical Decisions.
Cingarlini S; Ortolani S; Salgarello M; Butturini G; Malpaga A; Malfatti V; DʼOnofrio M; Davì MV; Vallerio P; Ruzzenente A; Capelli P; Citton E; Grego E; Trentin C; De Robertis R; Scarpa A; Bassi C; Tortora G
Pancreas; 2017 Jan; 46(1):42-47. PubMed ID: 27906872
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic performance of 18F-fluorodeoxyglucose positron emission tomography in the evaluation of glioma.
Shaw TB; Jeffree RL; Thomas P; Goodman S; Debowski M; Lwin Z; Chua B
J Med Imaging Radiat Oncol; 2019 Oct; 63(5):650-656. PubMed ID: 31368665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
